Recent innovations in the pharmacotherapy of type 2 diabetes are important, in view of the epidemic of type 2 diabetes and the individual and global economic costs of the disease. Although overall control of the disease has improved, more than 40% of patients on current therapies do not reach glycated haemoglobin (HbA_(1C)) targets as suggested by clinical practice guidelines.
展开▼